Overview

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Status:
Completed

Trial end date:
2003-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to establish the long-term tolerability and safety of istradefylline treatment in subjects with Parkinson's disease treated with levodopa/carbidopa. In addition, treatment response and maintenance of response were assessed.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Kyowa Kirin Pharmaceutical Development, Inc.
Kyowa Kirin, Inc.

Treatments:

Carbidopa
Istradefylline
Levodopa